Skip to Main Content

UCSF Research Development Office (RDO): Grant Templates and Guides: Funder Updates and Initiatives

National Institutes of Health (NIH)

National Institutes of Health (NIH)

 By providing an increase of $2.5 billion to the core budget of the NIH (5.6% over FY22), the BIPARTISAN OMNIBUS APPROPRIATIONS FOR FY23 agreement reaffirms strong, bipartisan support in Congress for funding critically important research conducted in every state across our nation. The American public agrees: A January 2022 survey commissioned by Research!America found that more than 9 in 10 Americans (92%) agree investing in research is important to finding new ways of preventing, treating, and curing illnesses.


Below are highlights from the UCSF Research Development Office related to new initiatives or updates by the National Institutes of Health. UCSF MyAccess required.

*NEW* Advanced Research Projects Agency for Health (ARPA-H)

Advanced Research Projects Agency for Health (ARPA-H)

Congress has provided an increase of $500 million to ARPA-H’s start-up budget of $1 billion. This new health innovation incubator, modeled after DARPA and ARPA-E, is working to jumpstart multi-sector-fueled, high-risk/high-reward science aimed at shattering barriers and forging progress against existing and emergent health threats. Importantly, the bill also includes authorizing language that will guide the next phase of this agency’s unique and important trajectory.

In September 2022, President Joe Biden appointed longtime biologist and former government scientist Renee Wegrzyn as the first director of the nascent Advanced Research Projects Agency for Health. Wegrzyn is a biomedical scientist and an entrepreneur in synthetic biology with a decade of experience leading multiple biotech projects at the Defense Advanced Research Projects Agency (DARPA).She has professional experience working for two of the institutions that inspired the creation of ARPA-H—DARPA and Intelligence Advanced Research Projects Activity (IARPA).

Research Areas and Priorities

ARPA-H will make big bets to build high-payoff capabilities or platforms to drive biomedical breakthroughs – ranging from molecular to societal – that will provide transformative solutions for all individuals. The focus areas below illustrate the types of work and impact that ARPA-H may pursue as it hires its first PMs.

Health Science Futures - Expanding what’s technically possible

Accelerating advances across research areas and removing limitations that stymie progress towards solutions. The tools and platforms developed apply to a broad range of diseases.

Scalable Solutions - Reaching everyone quickly

Addressing challenges that include geography, distribution, manufacturing, data and information, and economies of scale to create programs that result in impactful, timely, and equitable solutions.

Proactive Health - Keeping people from being patients

Reducing the likelihood that people become patients. Preventative programs will create new capabilities to detect and characterize disease risk and promote treatments and behaviors to anticipate threats to Americans’ health, whether those are viral, bacterial, chemical, physical, or psychological.

Resilient Systems - Building integrated healthcare systems

Developing capabilities, business models, and integrations to weather crises such as pandemics, social disruption, climate change, and economic instability. Resilient systems need to sustain themselves between crises – from the molecular to the societal – to better achieve outcomes that advance American health and wellbeing.


ARPA-H will be looking for projects that are transformational, driving biomedical breakthroughs. They will not support incremental research efforts. They seek to support "Imagine if..." projects. They will ask proposals to address the following set of questions about a well-defined problem.

ARPA-(H)eilmeier Questions - Towards a Well-Defined Problem

  1. What are you trying to do? What health problem are you trying to solve?
  2. How does this get done at present? Who does it? What are the limitations of present approaches?
  3. What is new about our approach? Why do we think we can be successful at this time?
  4. Who cares? If we succeed, what difference will it make?
  5. What are the risks? That may prevent you from reaching your objectives? Any risks the program itself may present?
  6. How long will it take?
  7. How much will it cost?
  8. What are our mid-term and final exams to check for success?
  9. To ensure equitable access for all people, how will cost, accessibility, and user experience be addressed?
  10. How might this program be misperceived or misused (and how can we prevent that from happening)?

National Science Foundation

National Science Foundation

The 2023 bill provides an increase of $1.036 billion to NSF (12.0% over FY22), a historic increase that is a significant down payment on the resources urgently needed to assure U.S. competitiveness in the global economic arena. This increase includes $9.54 billion in the CJS appropriations bill and $335 million in supplemental funding. While this increase is less than funding authorized through the landmark CHIPS and Science Act, it represents a clear commitment to fulfilling the charge of the CHIPS and Science Act in advancing U.S scientific and technological competitiveness. - Modified from Research!America News (

Since 2017, NSF has been building a foundation for the Big Ideas through pioneering research and pilot activities. In 2019, NSF invested $30 million in each Big Idea and continues to identify and support emerging opportunities for U.S. leadership in Big Ideas that serve the Nation's future. Check out these 10 Big Idea areas of investment:

Administrative Updates

NSF has released a revised version of the NSF Proposal & Award Policies & Procedures Guide (PAPPG) (NSF 23-1). The new PAPPG will be effective for proposals submitted or due, and awards made, on or after January 30, 2023.


Current Funding Opportunities - Highlights

Agency Title   Due Date(s) Link
NSF Technology, Innovation and Partnerships (TIP) Directorate      
  Partnerships for Innovation (PFI) NSF 23-538 5/2/2023; 9/5/2023; 1/2/2024
  Accelerating Research Translation (ART) NSF 23-558 5/9/2023; 9/18/2024
NSF Technology, Innovation and Partnerships (TIP) and STEM Education Directorates      
  Experiential Learning for Emerging and Novel Technologies (ExLENT) NSF 23-502 9/14/2023
NSF all Directorates plus Office of Integrative Activities      
  Faculty Early Career Development Program  (CAREER) NSF 22-586 7/26/2023
  Mid-Career Advancement (MCA)   3/1/2023
  Inclusion across the Nation of Communities of Learners of Underrepresented Discoverers in Engineering and Science (NSF INCLUDES)   10/22/2024
  Research Coordination Networks (RCN) NSF 23-529 anytime
NSF all Directorates plus Office of Integrative Activities plus DOD, USDA, NIST. DHS-S&T Directorate      
  Expanding AI Innovation through Capacity Building and Partnerships (ExpandAI) NSF 23-506 3/13/2023; 6/26/2023; 10/20/2023
NSF Dear Colleague Letter Supplemental Funding:      
  Provisioning Advanced Cyberinfrastructure to Further Research on the Monkeypox Virus    check current year availability
  NSF-NIST Interaction in Basic and Applied Scientific Research
  Workforce Development in Spectrum STEM
  Enabling Quantum Computing Platform Access for National Science Foundation Researchers with Amazon Web Services, IBM, and Microsoft Quantum
  Advancing Educational Innovations and Broadening Participation in STEM with Blockchain Technology
  A Supplemental Funding Opportunity for Supporting Research in Nascent Translation (SPRINT) through the Partnerships for Innovation (PFI) Program

Patient-Centered Outcomes Research Institute (PCORI)

Patient-Centered Outcomes Research Institute (PCORI)

The UCSF Research Development Office hosted a Get to Know PCORI event on October 2, 2017. Dr. Joe Selby, Executive Director of PCORI, gave an overview of the institute, and five PCORI-funded UCSF investigators discussed elements of preparing a successful PCORI proposal (panel discussion not recorded). A recording of Dr. Selby's presentation is below. The slide deck is available here.


A library of successful PCORI grants by UCSF investigators is available here.

Other Important Federal Agencies for Biomedical and Health Research

Centers for Disease Control and Prevention (CDC)

.The BIPARTISAN OMNIBUS APPROPRIATIONS FOR FY23 bill provides an increase of $760 million for the CDC (9.5% over FY22). The CDC is our nation’s principal public health agency — working to safeguard the US against pandemics, the opioid crisis, antibiotic-resistant “superbugs,” disparities in health and health care, and everyday threats to communities nationwide. This funding is a down payment that will begin the revitalization of an agency that has faced years of inadequate funding, bolstering its capacity to address a range of public health threats, improve and expand the public health workforce, and respond to potential global crisis....

Agency for Health Research and Quality (AHRQ)

The bill provides an increase of $23.1 million for AHRQ (6.6% over FY22), a significant and much-needed increase for AHRQ—another historically underfunded agency. AHRQ empowers the research needed to ensure that medical progress translates into high quality, cost-efficient healthcare. AHRQ-supported research has saved countless lives and generated health care savings that far surpass its annual funding.

Food and Drug Administration (FDA)

The bill describes a $226 million increase (6.5% over FY22) for FDA. This under-funded agency’s broad and critically important mission calls for additional resources. FDA oversees food, medical, and tobacco products valued at more than $2.8 trillion, which account for 20 percent of annual spending by U.S. consumers.

Modified from Research!America News (